Form 4: Processa CFO Russell Skibsted Increases Stake in PCSA

Processa Pharmaceuticals CFO Russell Skibsted acquired 2,292 shares of common stock at $2.57 per share.

Summary

• Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc., purchased 2,292 shares of common stock.
• The transaction occurred on May 29, 2026, at a price of $2.57 per share.
• Following this transaction, the reporting person's total direct beneficial ownership increased to 10,758 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal, as it reflects internal confidence from the CFO, though the transaction size is relatively small.

Positives

• Insider confidence is demonstrated by the CFO's decision to increase his equity position in the company.

Negatives

• None noted.

Risks

• Investment in small-cap pharmaceutical companies involves inherent market volatility and clinical development risks.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed by market participants as a signal of management's belief in the company's long-term pipeline potential.

Comparison to Industry Standards

• Insider purchases by C-suite executives are generally considered a positive signal of alignment with shareholder interests compared to industry peers where executives may only receive equity as compensation.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of management's commitment to the company's future.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Insider Trading, CFO, Form 4, Equity Acquisition